ArticlePharmacological reports : PR2025
Blockade of IgG Fc receptors reduces pain after intervertebral disc injury.
Article in Pharmacological reports : PR, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Recent advances in autoantibody-mediated pain.Current opinion in supportive and palliative care · 2026Review
- Article
- Fc gamma receptor IIa signaling from spinal cord astrocytes promotes neuropathic pain in rats.The journal of pain · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundIntervertebral disc (IVD) injury is a common cause of low back pain and disability. Recent evidence suggests that autoantibodies contribute to such pain. We, therefore, explored the hypothesis that a novel IgG Fc receptor blocker could reverse chronic pain-related behaviors in a mouse model of IVD injury.
methodsThese studies used a multi-level lumbar IVD puncture model of low back pain in male C57BL/6 mice. Additional mouse strains evaluated included Fc gamma chain knockouts failing to express excitatory IgG Fc receptors and muMT mice incapable of producing mature B lymphocytes or antigen-specific IgG. Nociceptive testing consisted of hindpaw mechanical allodynia and pinch hyperalgesia. The expression of FcgrI and FcgrIII excitatory IgG Fc receptors and FcgrIIb inhibitory receptors was measured in lumbar sensory ganglia and spinal cord tissue using qPCR. The accumulation of IgG was measured using immunoblotting.
resultsAfter disc injury, wild-type mice developed chronic hindpaw mechanical allodynia and pinch hyperalgesia. At 10 weeks post-injury, FcgrI, FcgrIIb and FcgrIII receptor expression were all increased in lumbar sensory ganglia and lumbar spinal cord tissue. Disc injury also caused IgG deposition at 10 weeks in the injured tissues and corresponding spinal cord. Treating disc-injured mice with the pan IgG Fc receptor interacting molecule (PRIM) reversed pain behaviors.
conclusionsInjury of mouse IVDs leads to persistent nociceptive sensitization in mice which can be reduced by administration of PRIM. Blockade of IgG Fc receptors may be a viable approach to the treatment of low back pain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.